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Abstract: Biochemical techniques focused on changes in the pro-
teome in benign and malignant conditions have been applied to the
study of lung cancer. Although relatively little information is cur-
rently available about the human lung proteome, the major goals of
the analysis of lung cancer are to better understand tumor biology,
to define early detection biomarkers and predictors of tumor behav-
ior, and to identify potential new therapeutic targets. In this review,
we summarized the last 10 years of research in this area with
emphasis on its application to the early detection of lung cancer.
Basic analytical tools, such as two-dimensional gel electrophoresis,
mass spectrometry, and protein arrays, are described and placed in
the context of lung cancer research.
(J Thorac Oncol. 2006;1: 1027–1039)
Proteins are responsible for the function of biologicalsystems and the phenotypes of cells. Cancer cells express
proteins that distinguish them from normal cells. In an effort
to characterize the molecular determinants of lung cancer, it
is critical that we probe these tissues and biological fluids
with tools that address the biology of lung cancer directly at
the protein level. Proteomics aims to characterize proteins to
obtain a more integrated view of the biology. Proteomics
attempts to answer how proteins are expressed, how they
function and interact, how they get post-translationally mod-
ified after different injuries, and how they can participate as
specific biomarkers of disease.1 As a result, new technologies
are being developed to allow the rapid and systematic anal-
ysis of thousands of proteins. In particular, the identification
of novel biomarkers to differentiate tumor from normal cells
and predict individuals likely to develop lung cancer repre-
sents major clinical questions still largely unanswered.
Proteomics-based early detection strategies for cancer
diagnosis include the analysis of complex mixtures such as
tissue samples, serum, plasma, sputum, and exhaled breath
condensate. The inherent analytical advantages of mass spec-
trometry (MS), including sensitivity and speed, promise to
make MS a mainstay of biomarker discovery. The develop-
ment of ionization techniques now allows almost any com-
pound to be studied by MS. The optimal use of these
technologies depends on the desired goal, such as protein
identification, identification of post-translation modification,
or determination of protein-protein interactions.
Biomarkers of early detection of lung cancer are still at
an early stage of development.2 The Early Detection Re-
search Network (National Cancer Institute, division of cancer
prevention) has proposed a step-wise method for evaluating
biomarkers and identifying people at risk (http://www.cancer.
gov/edrn).3 No current biomarkers for the early detection of
lung cancer have passed the early validation (phase II).4
Whereas genetics has provided considerable insights into the
molecular biology of lung cancer,5 the overall correlation
between level of expression of the messenger RNA molecules
and protein expression is relatively poor.6 Yet, we assume
that biomarkers exist and that proteomic technologies offer a
new avenue for biomarker discovery.
The hypothesis behind protein-based early diagnosis of
lung cancer is that a transformed cancer cell and its clonal
expansion results in up- or down-regulation of specific host-
or tumor-derived proteins, some of which will be secreted.
These proteins should be detectable in biological specimens,
including airway samples, sputum, and exhaled breath, or in
other samples obtained by methods ranging from venopunc-
ture, thoracentesis, bronchial brushing, lavage or biopsy,
transthoracic needle aspirates, or surgical biopsy specimen.
These proteins, including tumor antigens, can be detected by
a variety of methods with different sensitivity and specificity.
Historically, early detection has been most challenging be-
cause of the limited sensitivity of most tests applied to
screening strategies, and a molecular approach may address
some of the limitations of more traditional imaging or histo-
logical-based approaches. Recently, studies have shown that
cancer-specific “fingerprints” can be obtained directly from
tissue or serum and have great promise for the early diagnosis
of cancer.7–10 In this review, we discuss the proteomic meth-
odologies applied to lung cancer specimens, review the orig-
inal published data, and propose future directions.
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METHODOLOGICAL APPROACHES
From the traditional proteomic approaches discovering
and assessing proteins one by one, the field has rapidly
progressed in the last 10 years to high-throughput proteomic
strategies. Identification and validation of biomarkers is ac-
complished by a) two-dimensional (2D) gel electrophoresis
separation followed by analysis by time of flight mass spec-
trometry; b) proteomic profiling based on mass to charge
intensities; c) a combination of liquid chromatography fol-
lowed by MS in which proteolytic digestion and peptide
separation allow identification by tandem mass spectrometry;
or d) protein arrays (Table 1). When referring to the “top
down” approach, a protein is separated from a complex
mixture, purified, and identified by direct fragmentation in a
mass spectrometer. Ideally, this approach has many advan-
tages, but protein separation is difficult in practice. An alter-
native is the “bottom up” or “shotgun” approach, in which a
complex mixture of proteins is first made more complex
through enzymatic digestion, e.g., trypsin, followed by liquid
chromatography tandem MS to identify the peptide frag-
ments. A protein database search is then used to match the
fragments (Figure 1). Because complementary information is
often obtained, it is likely that a combination of these ap-
proaches will be necessary to for protein expression analysis.
Two-Dimensional Gel Electrophoresis
Two-dimensional gel electrophoresis has been the pri-
mary method of comprehensive proteomic analysis of tissue
samples. Proteins are separated on the basis of their charge
through isoelectric focusing (first dimension) and are then
further separated in a polyacrylamide gel on the basis of their
molecular weight (second dimension). When silver staining
techniques are used, more than 1000 proteins can be visual-
ized on a single gel. Stained gels are scanned with laser
densitometers, and spot detection can be analyzed and quan-
tified with software such as PDQUEST.11 Immobilized pH
gradients,12 narrow range pH gradients,13and fluorescent dye
labeling techniques14 have greatly improved the quality and
sensitivity of the information obtained.
Another development in 2D gels is the use of differen-
tial in-gel electrophoresis (DIGE), in which two pools of
proteins are labeled with different fluorescent dyes.15 The
labeled proteins are mixed together and analyzed in the same
2D gel. DIGE improves the reproducibility, sensitivity, and
quantitative aspects of 2D gel analysis.16,17 Although 2D
polyacrylamide gel electrophoresis (2D-PAGE) and related
technologies have proven to be excellent tools for the dis-
covery of proteins associated with pathological states and,
when combined with MS, can lead to the identification of
discriminating protein spots,18 only a small percentage of the
proteome can be visualized by 2D-PAGE, and 2D gels
remain a low-throughput approach that requires relatively
large amounts of sample (important for clinically applicable
proteomics).
Matrix-Assisted Laser Desorption Ionization
Mass Spectrometry
Development of ionization techniques such as electro-
spray ionization (ESI) and matrix-assisted laser-desorption
ionization (MALDI), coupled with new analyzers such as
TABLE 1. Comparison of Proteomic Platforms for Biomarker Discovery
2D-PAGE MALDI TOF MS ESI-MS (LC-MS/MS) Protein Arrays
Through-put Low; labor intensive Increased with
automation
High Increased with
automation (hundreds
of samples/day)
Moderate Single separations (RP)
Low Multidimensional
fractionations (10–15)
High Optimal
Sensitivity Low for low abundance proteins,
proteins with extreme pI,
molecular weights, and
hydrophobicity
Low Typically high
abundant proteins are
favored. Low
abundant proteins
suppressed unless
fractionation
techniques applied
High dependent on fractionations
to reduce sample complexity
High dependent on the
quality of the
detection method
(direct, antigen
capture or sandwich
immunosassays)
Detection limits 10–100 kDa Detection dependent on
stains used to visualize proteins
Optimal range 50 kDa
extended range 200
kDaResolution
decreases at higher
molecular weights
300–2000 Da. Higher molecular
weight proteins are observed
as multiply charged ions
No Dependent on the
sens. and spec. of the
detection system.
May require
amplification of
signal
Protein
quantification
No but improved with 2D-DIGE
technology using fluorescent dyes
No Isotope labeled
interval standards
allow targeted
quantitation
No but improved with isotopic
labeling analyses
Yes
Reproducibility Good Good Poor Good
Advantages Automation, post-translational
modifications
Rapid and small amount
required
Depth of the analysis Automation, robustness
Limitations Cumbersome to run, large amount of
protein needed
Low % of proteins
analyzed, no rapid
identification
Needs fractionation Not
compatible with all buffers
Requires prior
identification of
proteins, technical
challenges
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TOF ion trap, and quadrupole technologies, have facilitated
the characterization of proteins by MS. These ionization
techniques transfer proteins into a gas phase as charged
molecules, enabling analysis in the mass spectrometer. Di-
gested peptide samples can be analyzed in a mass spectrom-
eter through a microelectrospray,19 allowing for direct se-
quencing and identification. For example, a MALDI
quadrupole TOF instrument (so-called TOF technology) that
allows a combination of peptide mapping with peptide se-
quencing has been developed.20,21 This instrument allows
identification of a protein either by peptide mass fingerprint-
ing of the protein digest or from tandem mass spectra ac-
quired by collision-induced dissociation of individual peptide
precursors. A peptide mass map of the digest and tandem
mass spectra of multiple peptide precursor ions can be ac-
quired from the same sample in the course of a single
experiment.
In MALDI MS, analysis requires that the sample is
crystallized with a matrix that absorbs energy and subse-
quently ejects and ionizes the molecules into the gas phase. A
strong electrical field accelerates all the ions in a pulse so that
ions reach the detector at a speed that is inversely propor-
tional to their mass-to-charge (m/z) ratios (i.e., lighter ions
arrive earlier and heavier ions later). This time-of-flight is
then calibrated to m/z. Complex mixtures can be analyzed by
MALDI MS without fractionation.22 This type of analysis
allows the simultaneous determination of protein molecular
masses from 1 to 200 kDa with high accuracy.
Two features of MALDI TOF MS that make it espe-
cially promising for MS analysis of biological samples are its
capability for very high throughput, in which a sample can be
analyzed in seconds, and its higher tolerance for salts, buff-
ers, and other biological contaminants. Because of these
qualities, MALDI MS has been used to study proteins/
peptides in serum, blood, urine, tissue extracts, whole cells,
and laser-captured microdissected cells. MALDI MS has also
been successfully applied to cells from the mammary epithe-
lium or colon crypt.23
MALDI MS imaging/profiling, depicted in Figure 2, is
a new technology for direct mapping and high-resolution
imaging of biomolecules present in tissue sections.24,25 In this
system, frozen tissue sections or individual cells are mounted
on a metal plate and spotted with droplets of matrix in a
regular array spaced at 50 to 100 m; mass spectra are
acquired from each pixel; and the spectrum from each pixel is
then queried for the presence of specific mass spectral peaks.
If a small number of discrete areas are to be analyzed, then
these are ablated individually in a profiling mode. If the
relative intensity of any of the signals in the spectrum is to be
measured over the entire tissue at higher image resolution,
then a raster is performed to provide a matrix of pixels. An
image representing the intensity of a given peak in each pixel
in the array is then generated. Imaging MS shows potential
for several applications, including biomarker discovery, bi-
omarker tissue localization, understanding molecular com-
plexity of tumor tissues, and assessment of surgical margins
in resected tumors.24
Liquid Chromatography Tandem Mass
Spectrometry
Liquid chromatography (LC) MS-MS (Tandem MS)
couples HPLC with MS and has had a great impact on profiling
of small molecule and protein, on identification of protein and
their posttranslational modifications, and has proven to be an
important alternative method to 2D gels.26,27 Typically, a
mixture of proteins is first digested with site-specific pro-
teases, then the resulting peptides are separated by using LC,
and fractions are then analyzed by tandem MS (MS/MS). In
this procedure, a mixture of charged peptides is separated in
the first MS according to their m/z ratios. Each of these ions,
or only those desired, are then sequentially directed into a
collision cell that fractures these peptides into fragment ions
FIGURE 1. Schematic representation of identifi-
cation of the components of a complex protein
mixture through top-down and bottom-up pro-
teomic approaches. 2D-Page, two-dimensional
polyacrylamide gel electrophoresis; MS-MS, tan-
dem mass spectrometry; MALDI TOF MS; matrix-
assisted laser desorption time-of-flight mass spec-
trometry; LC MS-MS, liquid chromatography
tandem mass spectrometry; Thermo LTQ, linear
ion trap mass spectrometer.
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derived from the “parent” species. Fragmentation occurs
predominantly at the peptide bonds such that a ladder of
fragments is generated. The fragment ions are separated
according to their m/z in the second scanning MS. Because
the mass spectrometer can identify amino acids by measuring
the precise differences in the molecular weights of these
fragments, the sequence of the peptide can then be deduced
from the resulting fragments. By comparing predicted se-
quences in the databases, the identity of the peptide and,
therefore, the protein from which it came, is deduced.
Electrospray ionization (ESI) is a technique by which
peptides and proteins in solution are converted into multiply
charged ions in a gas phase for analysis in a mass spectrom-
eter. Basically, the ionization process uses small solvent
droplets containing the molecule of interest. As the droplet
dissolves in the process, the protons in the droplet interact
with basic sites on the molecule, creating multiply protonated
(multiply charged) ions. Thus, a protein of 50,000 MW may
typically have 15 to 30 or more protons, bringing the m/z
value of the molecule to approximately 2000, a range attain-
able by most MS instruments. These gas phase ions move to
the analyzer under the influence of varying pressures and
electric fields at the boundary leading to the mass analyzer.28
The multiple charges on the gas phase peptides bring the
mass-to-charge ratio down to a few thousand from a molec-
ular weight of tens of thousands. Because mass spectrometers
directly measure mass per charge, this method allows the
measurement of large molecules without exceeding the mass
limit of the detector (usually approximately 2000 atomic
mass units). ESI is usually coupled with a triple quadrupole,
ion trap, or hybrid TOF (QTOF) MS. The ability to conduct
tandem MS after ESI has revolutionized proteomics, because
this MS/MS method can be used to directly obtain amino acid
sequence information. ESI presents significant advantages in the
ease of coupling compared with separation techniques such as
LC and HPLC by allowing online analysis of protein or peptide
mixtures. However, it is a relative low-throughput technology.
Protein Arrays
Protein microarray technology provides an in vitro
means of studying function as reflected in protein alterations
related to disease status. For this application, the proteins
themselves are arrayed on a solid support. The protein spots
may consist of antibodies, cell or phage lysates, or recombi-
nant proteins or peptides.29 Detection of the array is achieved
by probing with a tagged antibody, ligand, or serum/cell
lysate. The signal generates a pattern of positive and negative
spots. The signal intensity of each spot is proportional to the
quantity of applied tagged molecules bound to the molecule.
Significant difficulties in this technology relate to the detec-
tion of low abundance proteins with adequate sensitivity and
specificity–the ability to page endogenous molecules such as
peroxidases, biotin, or immunoglobulins, and that may be
important because of their ability to interfere with the detec-
tion amplification chemistries. Autoantibodies can be partic-
ularly useful for studying cell-surface antigens on cancer cells
and could become a powerful tool for screening large num-
bers of antigens by protein microarray.30 A reverse-phase
protein array approach that immobilizes the whole repertoire
of a tissue’s proteins has been developed.31
Despite its advantages, protein microarray technology
has some limitations. This technology requires high-quality
and comprehensive expression libraries and methods that
FIGURE 2. Schematic representation of matrix-assisted de-
sorption ionization mass spectrometry. Fresh tissue is sec-
tioned and mounted on a conductive metal plate. The sam-
ple is coated with matrix in a raster design, typically
sinapinic acid, and directly analyzed in the mass spectrome-
ter. The relative intensity of any of the signals in the spec-
trum is measured over the entire tissue at higher image reso-
lution. If a small number of discrete areas are to be
analyzed, then these are ablated individually in a profiling
mode. If the relative intensity of any of the signals in the
spectrum is to be measured over the entire tissue at higher
image resolution, then a raster is performed to provide a
matrix of pixels in an imaging mode. An image representing
the intensity of a given peak in each pixel in the array is
then generated.
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allow the robust analysis of a large number of functionally
active proteins. Lack of availability of high-affinity and
high-specificity antibodies for gene products and post-trans-
lationally modified proteins is one of the major limitations of
this technology.32
APPLICATION OF PROTEOMIC
METHODOLOGIES TO LUNG CANCER AND
RELATED BIOSPECIMENS
Lung Tissue
A comprehensive analysis of the proteome in lung cancer
is being pursued.33 Hanash et al.33 have analyzed more than
1000 lung cancer-related samples using 2D PAGE, in com-
bination with MS, and have constructed the lung proteomic
database. The aim of their studies was to identify biomarkers
for the early detection of cancer, for developing novel clas-
sification of tumors, and for revealing novel targets for
therapeutic intervention (Figure 3).6,34 They performed par-
allel analysis of the transcriptome and of the proteome in lung
tumors, comparing mRNA and protein levels in the same
tumors.6 The integrated intensities of 165 protein spots rep-
resenting the protein products of 98 genes were analyzed in
76 lung adenocarcinomas and nine unaffected lung tissues
using 2D PAGE. For the same 85 tissue samples, mRNA
levels were determined using oligonucleotide microarrays.
Only 21 of the 98 genes analyzed (21.4%) showed a statis-
tically significant correlation between protein and mRNA
levels. Glucose-regulated M(r) 58,000 protein stands out as a
protein elevated at the mRNA and translational level. This
does not mean that microarray studies are uninformative,
rather that they convey additional information with only
partial overlap with proteomic data.
Recently, Beer et al.35 identified a battery of genes and
related proteins validated using a training and independent
testing set associated with survival of adenocarcinoma of the
lung. Using 2D gel analysis, the same group identified five
CK7 cleavage products best associated with patient survival,
a subset of which correlated to gene expression.34 Using 2D
FIGURE 3. (A), 2D-PAGE gel separation of proteins identified with silver staining from a stage I lung adenocarcinoma. The
proteins are separated by isoelectric point (PI) in the first dimension and by molecular weight (MW) in the second dimension.
(B–F), the outlined areas of (A) showing proteins significantly increased in lung adenocarcinoma (Chen G, Gharib TG, Huang
CC, et al. Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin
Cancer Res 2002;8:2298–2305. Reprinted by permission.
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PAGE and MS, Chen et al. identified and characterized
several lung cancer-specific protein markers of lung adeno-
carcinomas, such as antioxidant enzyme AOE372, ATP syn-
thase subunit d(ATP5D), beta1,4- galactosyltransferase, cy-
tosolic inorganic pyrophosphatase, glucose-regulated M(r)
58,000 protein, glutathione-S-transferase M4, prolyl 4- hy-
droxylase beta subunit, triosephosphate isomerase, and ubiq-
uitin thiolesterase (UCHL1).6 They went on to identify 33 of
46 survival-associated proteins by MS. Expression of 12
candidate proteins was confirmed as tumor-derived with im-
munohistochemical analysis and tissue microarrays.36
Using a MALDI MS technology, Bergman et al.11
detected increases in the expression of cathepsin D in lung
adenocarcinoma. Many of these proteins represent specific
isoforms of known proteins and reflect post-translational
modifications and potential degradation forms. They also
confirmed these candidates by using both mRNA microarrays
and tissue microarrays.35,36 None of those candidate biomar-
kers has a current application in the clinic.
After subcellular fractionation and substractive pro-
teomics, investigators have identified endothelial cell surface
proteins aminopeptidase-P and annexin A1, exhibiting re-
stricted lung tissue distribution and over-expression in lung
tumors. Radio-immunotherapy to annexin A1 destroyed tu-
mors and increased animal survival.37 Most recently, a small
series of surgically resected lung tumors were recently ana-
lyzed by 2D gel and MALDI MS to identify a series of
proteins previously reported such as annexin II, cathepsin D,
HSP27, stathmin, and MnSOD, confirming the validity of this
methodology to identify candidate biomarkers.38
With recent advances in MS techniques, it is now
possible to investigate protein expression profiles from small
biological specimens over a wide range of molecular weights.
Using this technology on tumor lysates, profiles of 10 non-
small cell lung cancers were analyzed, and two proteins,
MMIF and cyclophilin A, were identified as candidate bi-
omarkers39 and later found not to be prognostic markers of
disease based on a lung cancer tissue microarray (Figure 4).40
FIGURE 4. Tissue microarrays (TMAs) of lung cancer specimens. TMAs are comprised of core biopsies 0.6 mm in diameter of
different tumors and of uninvolved lung from the same individuals. TMAs allow high-throughput analysis of molecular markers
identified in lung cancer and control samples. Clinical annotation of these specimens allows rapid assessment of clinical out-
comes (e.g., survival) as schematically represented by Kaplan-Meier survival curves. FISH, fluorescent in situ hybridization; IHC,
immunohistochemistry.
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We and others have recently demonstrated that pro-
teomic profiling of lung tumors using MALDI MS or 2D gel
methods allows distinction between normal and cancer tissue,
and it may predict lymph node involvement or survival.8,36,41
In a recent report, we used conventional MALDI MS to
generate protein profiles that accurately classify and predict
histological subgroups of lung cancer (Figure 5).8 Using
biostatistical methods to select differentially expressed peaks
(MS signals), and after the development of a class prediction
model,42 82 discriminatory signals were found to classify
normal lung from lung cancer tissue samples in a derivation
and validation study design with excellent accuracy. Other
recent studies indicated the importance of using protein
expression profiles as diagnostic or prognostic biomarkers for
patients with early-stage lung cancer using a type of MALDI
MS termed surface-enhanced laser desorption/ionization
(SELDI) technology.43 Although preliminary, these studies
stress the relevance of protein signatures for the diagnosis and
evaluation of response to therapy in lung cancer.
Functional proteomics is emerging as a powerful tool
that uses proteomic technologies to investigate the interac-
tion, integration, and functions of proteins. This strategy
couples proteomic information with biochemical and physi-
ological analysis to advance our understanding of the func-
tional role of proteins in normal and diseased organs. The
proteomic profiling of protease activity in cancer is an attrac-
FIGURE 5. Detection of the opti-
mal discriminatory biomarker sets
in lung tumors. (Top), Representa-
tive MALDI-TOF-MS spectra ob-
tained from tumor and normal
lung tissue samples with molecular
weight calculation (m/z values).
*Examples of the MS peaks identi-
fied by the statistical analyses as
optimal discriminatory patterns be-
tween normal and tumor. (Bottom),
Hierarchical cluster analysis of 42
lung tumors and eight normal lung
tissues in the training cohort ac-
cording to the protein expression
patterns of 82 MS signals. Each
row represents an individual pro-
teomic signal, and each column
represents an individual sample.
The dendrogram at the top shows
the similarity in protein expression
profiles of the samples. Substan-
tially raised (red) expression of the
proteins is noted in individual tu-
mor and normal lung tissue sam-
ples. AD, adenocarcinoma; SQ,
squamous cell carcinoma; LA, large
cell carcinoma; META, metastases
to lung from other sites; REC, re-
current non-small cell lung cancer;
CAR, pulmonary carcinoid; NL, nor-
mal lung. (Yanagisawa K, Shyr Y,
Xu BJ, et al. Proteomic patterns of
tumour subsets in non-small-cell
lung cancer. Lancet 2003;
362:433–439. Reprinted by per-
mission.)
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tive example of this approach. Because proteases are in-
volved in many aspects of tumor development, assaying their
nature and post-translational modifications is of great interest.
Activity-based proteomic profiling allows such screening with
molecular tags specific for enzymatic activity.44 In particular,
this approach can be associated with multidimensional pro-
teomic LC-MS analysis to discover the relative roles of active
proteases in tumor cells and its microenvironment.45
Serum and Plasma
Analysis of the serum proteome assumes that tissue
perfusion of tumors or host responses contribute to the
modification of circulating protein or peptide concentrations.
Therefore, the proteins present in the serum are hypothesized
to reflect the pathological state of the organism. Thus, inves-
tigators attempt to uncover a discriminating pattern in a small
subset of proteins (among thousands) that are useful for
diagnostic purposes. Evaluation of the lower molecular
weight protein profile can be accurately analyzed by using a
variety of methods, including ESI/MS/MS and MALDI MS,
and may correlate with these pathological states. It remains to
be seen whether there is sufficient information in this slice of
the blood proteome.
Although they can be very challenging, serum pro-
teomic studies have great promise for the early detection of
cancer, the monitoring of disease status, the discovery of new
targets for therapy, and the assessment of response to therapy.
This new approach faces the difficulties of lack of standard-
ization, continuously evolving technologies, limitations of
bioinformatics tools, the complex nature and large dynamic
range of the blood proteome, assay reproducibility, and iden-
tification and quantitation of candidate biomarkers. Pro-
teomic studies using blood as a source of proteins still have
not resolved the question of whether analysis of serum or
plasma is more informative.46 Plasma requires the addition of
an anticoagulant and, eventually, a two-step centrifugation to
get rid of platelets. Clotting depletes fibrinogen from the
serum but also depletes other proteins and is associated with
the appearance of many peptides, likely cleavage fragments
of circulating proteins. A systematic, rigorous, and prospec-
tive collection protocol for both plasma and serum is essential
to answering these critical questions.
The Human Plasma Proteome Project is an interna-
tional collaboration to characterize proteins in the human
serum and plasma. This organization is addressing in detail
issues of protein identification; specimen collection, han-
dling, and storage; depletion of highly abundant proteins;
fractionation; and MS instruments for the identification of
peptides from digested proteins. They have already identified
more than 9500 proteins, 3020 of which have at least two
peptide matches.47
Another argument revolves around the need for frac-
tionation of the serum/plasma. The simple fact that 22 of
these tens of thousands of proteins in serum constitute 99% of
the total protein content in the serum and that there is a large
concentration range of these proteins (approximately 108
fold) results in great difficulties in fractionating the serum and
in identifying tumor-specific markers, many of which are
likely to be present in low abundance. Fractionation is intu-
itively more satisfying, reducing the complexity of the bio-
logical mixture, increasing the number of peaks obtained by
MALDI MS, and increasing the likelihood of finding new
biomarkers among lower abundant proteins. However, there
are also disadvantages because fractionation requires larger
sample amounts, is more time- and cost-consuming, and
dramatically increases the risk of variability within and be-
tween samples, which may preclude the use of the resulting
proteomic patterns for diagnosis. A dual approach is probably
worth emphasizing at the early stage of development of this
proteomic strategy.
Recently published studies have reported serum protein
expression profiles that distinguish cancer patients with a
variety of malignancies from controls using various MS-
related approaches.9,10,48–52 In the latter publication, the au-
thors identified a serum protein pattern among patients with
head and neck cancer who achieved a sensitivity of between
34% and 52% when applied to the serum of patients with lung
cancer. Protein patterns were distinguished by using MALDI
TOF MS combined with a simple classification procedure,
based on a t test and linear discriminant analysis in tumor sera
that included patients with head and neck or lung cancer.10 By
using the optimal head and neck cancer model cutoff of 73%
sensitivity and 90% specificity, they were able to discriminate
squamous cell lung cancer with sensitivities of 52% (34% for
adenocarcinoma and 40% for large cell carcinoma).10 How-
ever, this study was not designed to address whether this
protein profile can discriminate patients with lung cancer
from controls.
This is a unique study that generates proteomic profiles
in serum by using MALDI TOF MS, a very simple, rapid, and
inexpensive technology that requires only basic sample pro-
cessing and shows potential to achieve practical early cancer
detection in biological fluids. A single protein by itself may
not be useful for early detection, but it is thought that the
most informative biomarker may be a combination of mark-
ers into signature protein profiles for early diagnosis. These
studies are very encouraging and demonstrate that MALDI
MS fingerprint protein profiling, coupled with a learning
algorithm, can be useful for the early diagnosis of prostate,
ovarian, breast, bladder, and aerodigestive cancers by using
only 1 L of serum.
Our group recently generated protein expression pro-
files using MALDI TOF MS directly from 1 L of unfrac-
tionated serum to define a discriminatory protein fingerprint
to distinguish patients with lung cancer from matched con-
trols.53 We found several proteins that could discriminate
patients with early-stage lung cancer from controls; most of
the proteins were in lower m/z ranges. Recently, automated
tools for the discovery of serum markers have been devel-
oped. These apply small-volume robotics to serum fraction-
ation and MALDI MS analysis. This approach may provide
better reproducibility, multidimensionality, and high through-
put to the analysis of biological specimens.54 This approach
must be validated in larger populations and from a number of
institutions before the further translation of this tool into
general clinical decision-making for the early diagnosis of lung
cancer. Shotgun proteomics is being investigated as a mode of
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in-depth analysis of the serum proteome for the purpose of
biomarker discovery55 and as potential platform to be translating
to the clinic. Questions revolving around reproducibility and
rapidly changing technology are being considered.
The search for autoantibodies as source of biomarkers
is an attractive approach, as we know the sensitivity of the
immune system to respond to increasing concentration of the
peptide presented to the immune surveillance system. Au-
thors have long searched for specific autoantibodies of can-
cer-related peptides (e.g., p53).56 More recently, investigators
have proposed high-throughput screening of autoantibodies
to circulating tumor antigens in patients with lung cancer.57
Briefly, 2D PAGE of the lung adenocarcinoma cell line
(A549) was incubated with sera from patients with lung
adenocarcinoma, other cancers, and no cancer controls. These
studies found autoantibodies against glycosylated annexins I
and II in 60% of the patients with lung adenocarcinomas and
33% of patients with squamous cell carcinomas and that this
was associated with high circulating levels of IL-6.58 Simi-
larly, studies involving sera from 64 newly diagnosed pa-
tients with lung cancer, 99 patients with other types of cancer,
and 71 non-cancer controls revealed a tumor antigen, protein
gene product 9.5 (PGP 9.5, a neurospecific protein) that
induces a humoral response in lung cancer.57
In an effort to speed up the analysis of serum for
autoantibodies to lungs bearing antigens, a novel approach
that combines liquid phase protein separation with microarray
technologies was developed.59 Whole cell or tissue lysates are
fractionated by isoelectric focusing and reverse phase chro-
matography into hundreds of fractions, which are then ar-
rayed onto nitrocellulose-coated slides and probed with anti-
bodies against specific proteins. Such biochips require low
sample volume and provide a rapid procedure to molecularly
profile the antibody response to tumor antigens in cancer.
Circulating antibodies to tumor-associated proteins were
also isolated from the serum of patients with lung cancer
from cDNA T7 phage libraries, and 45 candidates were
identified. This is done by sequencing cDNA from phages
of interest. Protein expression in serum is being confirmed
by ELISA.60,61
Pleural Effusions
Proteomics has the advantage of allowing the analysis
of both tissue and biological fluids and the identification of
proteins and protein post-translational modifications such as
phosphorylation, glycosylation, and sulfation that could be
specific for different tumor types. Nilsson et al. analyzed
pleural exudates by applying 2D gel electrophoresis, MALDI
TOF MS, and Western blotting.62,63 They confirmed the
identity of proteins of potential diagnostic value such as
cystatin C. Although it is possible to obtain mass spectra of
proteins in complex biological mixtures (e.g., pleural effu-
sion, cerebrospinal fluid) without previous purification
steps,23,64 simple fractionation often results in a dramatic
improvement of the signal-to-noise ratio. Because larger
volumes of low concentrations of proteins can be loaded onto
analytical 2D gels, low-abundance proteins in biological
fluids, such as pleural exudates, may be enriched for further
characterization by MS.
Recently, Bard et al. studied the presence of exosomes
(membrane vesicles from endosomes) in cancerous pleural
effusions and to identify their proteomic content.65 They
found the presence of antigen-presenting molecules, cy-
toskeletal proteins, and signal transduction-involved proteins
as well as SNX25, BTG1, PEDF, and thrombospondin 2. A
high concentration of antigen-antibody humoral immunity
components in exosomes may be important as an antigen
source for cancer immunotherapy. Promising biomarkers of
mesothelioma (i.e., mesothelin and osteopontin) are being
introduced into clinical practice.66–68 Both were discovered
by proteomic analysis and moved to phase 3 biomarkers
validation. Osteopontin shows promise in distinguishing in-
dividuals with exposure to asbestos who do not have cancer
from those with mesothelioma.
Exhaled Breath and Sputum
Condensation of exhaled breath is a non-invasive way
to collect material originating from the lung, including the
lower respiratory tract. To date, exhaled breath condensate
samples have been mainly studied for NO metabolites,69,70
8-isoprostane,71 and various inflammatory cytokines.72 EBC
and saliva proteins have been characterized by using 2D
electrophoresis,73 but characterization of the methods and the
specimens has not yet been completed. Examining a set of
volatile markers may enable recognition and diagnosis of
diseases such as lung cancer. In the hope of evaluating the
field of cancerization, the EBC has recently been studied in
patients with lung cancer. Tumor suppressor gene p53 muta-
tion was detected by PCR in exhaled breath condensate of
patients with lung cancer.74 Endothelin-1 and microsatellite
markers were found in EBC and therefore confirm the poten-
tial diagnostic value of this biological specimen.75,76 Al-
though very appealing, there are technical challenges related
to sampling and analysis, lack of normalization, and stan-
dardization; therefore, huge variations exist between results
of different studies.5 Translating the analysis of EBC to
clinical practice is likely to be problematic.
The sputum is more difficult to analyze by proteomic
methods than exhaled breath condensate. Traditional pro-
teomics has used immunostaining of sputum samples for the
validation of tumor-related antigens. Some of these markers
are still being investigated in prospective trials.77 2D electro-
phoresis of sputum induction specimen is attractive, although
specific alterations in protein composition in lung disorders
are not well characterized. The soluble and cellular compo-
nents may represent useful and separate components to ana-
lyze using MALDI MS. This work must be developed in the
future.
Bronchial Biopsies
In preliminary studies we used MALDI MS to identify
specific patterns of protein expression of the airway epithe-
lium in different histological stages of tumor progression.
MALDI MS data were acquired from normal alveolar epi-
thelium, normal bronchial epithelium, and preinvasive and
invasive lung cancer tissues mainly from patients with con-
comitant lung cancer. Statistical analysis and supervised
hierarchical cluster analysis revealed that protein profiles are
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able to distinguish among groups with excellent accuracy.41
Based on this cross-section analysis of bronchial biopsies, we
were able to predict the nature of the histological lesion. We
hope to validate these data in an independent set of tissues
and select proteins expressed in invasive and preinvasive, but
not histologically normal epithelium. Ultimately, these pro-
teins may provide us with targets for diagnostic markers and
therapeutic intervention.
Bronchioalveolar Lavage
Bronchioalveolar lavage (BAL) performed during fi-
beroptic bronchoscopy is a relatively safe technique that
allows the collection of cells and a wide variety of soluble
components, including proteins, from the human lung.78 Be-
cause the proteins present in BAL have many origins, and
because of the diversity of proteins considered, analysis of
the protein content of BAL is of great potential interest in
defining biomarkers in many lung diseases. The potential for
discovery of new lung disease markers in BAL via proteom-
ics approaches is significant. The first 2D map displaying the
major soluble proteins present in lung lavage was published
in 197979 and pattern-matched with 2D maps of serum sam-
ples.80 After many different technical improvements, work
still aims at the construction of a 2D reference database of
BAL proteins and the understanding of the molecular pro-
cesses involved in lung disease.81
Recently, the identification of proteins present in the
BAL 2D map has been published.82–84 The most important
technical advancement that enabled BAL proteomic analysis
was the improvement in the method used for isoelectric
focusing. In 1990, Lenz et al.85 used improved methods for
isoelectric focusing for the first-dimensional separation of
proteins from dog BAL. The BAL sample preparation (salt
removal, sample concentration, fractionation), sample load-
ing technique, choice of pH range, and second-dimensional
gel used are critical in obtaining optimal resolution of the
widest range of proteins present in BAL.84,86 Several proteins
related to lung inflammation have been identified; they are
altered in smokers and are specific for different inflammatory
conditions (sarcoidosis, interstitial pulmonary fibrosis, hyper-
sensitivity pneumonitis). This BAL technique has not been
studied in detail among patients at risk of or with lung cancer.
CHALLENGES AHEAD
Proteomics studies currently use various methods for
sample collection, preparation, storage, and processing, and
for patient selection. The optimal steps in sample collection,
processing, and analysis must be standardized.87,88 Because
of the inherent instability of proteins, sample procurement
and preservation issues must be addressed to make them
compatible with proteomics analysis.
Databases do not necessarily agree on criteria necessary
to assign a protein identification. The Human Proteome
Organization Plasma Proteome Project has more than 9600
proteins identified according to proposed internal criteria, but
identification of proteins and statistical methods89 leading to
the identification of proteins still are needed to reach agree-
ment. The development of bioinformatics tools and optimi-
zation of biostatistical analysis are essential. The simplifica-
tion of processing samples for a diagnostic test is an
important goal of clinical proteomics. Obviously, the size of
the datasets obtained after fractionation leads to difficulties in
data analysis. The complex nature of the sample fractionation
and data analysis also call for a major effort in mobilization
of a process otherwise subject to relatively high variability.
The integration of genomic with proteomic data repre-
sents a great challenge for the future. Many proteins that are
expressed in different types of lung cancer have been iden-
tified and have been correlated with the expression measures
for their corresponding genes at the RNA level. Because of
the non-linear relationship among gene expression, transla-
tion to protein, and changes in function, it is important to
assay for not only protein over-expression, but also their
functional post-translational modifications.
When analyzing biological samples, it is desirable to
avoid excessive purification steps because loss of material is
unavoidable at each step. The analysis of biological samples
is also complicated by the fact that the sample contains many
proteins, many in a low concentration. The scarcity of pro-
teins of interest in biological materials makes isolation of
sufficient material for proteomic analysis problematic, partic-
ularly for 2D electrophoresis. The peptidomic analysis of
albumin-bound peptides may have some advantages.90,91 The
more we fractionate proteins, the more we risk increasing
variability.
Quantitation of molecular species, particularly candi-
date biomarkers, is of critical importance. It is hoped that
standard chemical assays, ELISA assays, and MS analysis
will render the assays sensitive and reliable. Fluorescence-
based and MS-based methodologies are being actively pur-
sued: DIGE, multiplexed proteomics,92,93 isotope-coded af-
finity tagging (ICAT)15,94 and targeted quantitative analysis
of proteins by isotopic dilution with labeled peptide internal
standards (AQUA method)95 are being developed to this end.
CONCLUSIONS
Integration of genomics and proteomics approaches
will allow us to move closer to the goals of earlier detection.
The rapid development of proteomic and genomic technolo-
gies has provided a large amount of novel information, has
allowed comprehensive analysis of the molecular basis of
disease, and is leading to the assembly of large protein
inventories. Molecular profiling may assist in identifying
high-risk populations, and it offers a unique opportunity to
study early carcinogenesis and potentially to reduce cancer
mortality through the available effective treatment modalities
amenable to early cancer.
Proteomic analysis has the potential to profile differ-
ences between lung tumor and no tumor, among different
stages and histology of cancer, and among different cancer
samples at the same stage of progression. The ability to
identify important proteins involved in the transformation
process may lead to early markers for the detection of specific
types of cancers and treatments based on the molecular
profile of lung cancer.
In the past decade, lung cancer treatment has become
increasingly target-oriented. However, all targets have been
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identified in late invasive and metastatic disease, thereby
limiting the success of treatment. It is widely believed that if
specific targets important in the earliest stage of the tumor can
be identified, then application of these treatments early in the
course of disease or premalignancy is likely to be more
successful than attempting to treat late-stage tumors. Screen-
ing methods with high sensitivity and high specificity for
early-stage lung cancer and that are also noninvasive, afford-
able, and safe, are urgently needed. Although measurements
of chromosomal aberrations, point mutations, and loss of
heterozygosity can be obtained from a series of biological
specimens, the integration of these data with proteomic anal-
ysis will be critical in creating better clinical tools for the
early detection and management of lung cancer.
Clinical proteomics will have a fundamental impact on
our understanding of complex disease processes, such as lung
cancer, and will offer new opportunities in the diagnosis,
prognosis, and therapy of disease. The development of spe-
cific and sensitive diagnostic biomarkers using biological
fluids, such as sputum and serum, should improve screening,
early detection, monitoring of disease progression, treatment
response, and surveillance for recurrence.
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